(Hyperhidrosis)
5,964 results
  • Monitoring complications of botulinum toxin in community practice: A pharmacological study. [Journal Article]
    Bioinformation. 2026; 22(6):3718-3722.Remesh A, Sethi TK, … Syed AKB
  • Botulinum toxin is widely used for cosmetic wrinkle reduction, hyperhidrosis, chronic migraine and facial muscle disorders, but concerns persist regarding adverse effects related to injection technique, toxin diffusion and practitioner variability. Therefore, it is of interest to evaluate the complication rates of community-based botulinum toxin therapy and characterize the clinical presentations…
  • Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions. [Journal Article]
    Clin Dermatol. 2026 Sep 03. [Online ahead of print]Elgindi D, Petronic-Rosic VCD
  • CONCLUSIONS: Non-immunologic cutaneous adverse events comprise a substantial proportion of reported GLP-1RA-associated adverse events with differing rates among individual agents. Recognition of these reactions and appropriate supportive management may improve patient outcomes. Prospective studies are needed to better define their adverse event risk rates, mechanisms, and optimal management strategies.
  • Vibration, Pressure, and Cryoanalgesia to Minimize Acral Injection Pain. [Journal Article]
    Pediatr Dermatol. 2026 Aug 31. [Online ahead of print]Rice S, Flanagan K, Goldberg DPD
  • Acral injections for conditions such as palmoplantar hyperhidrosis are associated with significant procedural pain, frequently limiting their use in pediatric populations. While nerve blocks, cryoanalgesia, and topical anesthetics can mitigate discomfort during palmar injections, each has practical limitations. This report describes a multimodal technique combining cryoanalgesia, pressure, and vi…
  • Infrared Thermography as a Clinical Clue to Eccrine Angiomatous Hamartoma in a Child. [Journal Article]
    J Dermatol. 2026 Aug 18. [Online ahead of print]Wu MY, Ohara KJD
  • Eccrine angiomatous hamartoma is an uncommon benign cutaneous hamartoma characterized by proliferation of eccrine and vascular components. It usually presents at birth or in childhood as a solitary extremity lesion and may be associated with pain, tenderness, hypertrichosis, or hyperhidrosis. We report a 6-year-old boy with a recurrent warm, hyperhidrotic subcutaneous tumor on the lateral aspect …
  • Oritavancin safety: a real-world pharmacovigilance study of the FAERS database. [Journal Article]
    Front Cell Infect Microbiol. 2026; 16:1798934.Xie B, Zhou YF, … Cui XJFC
  • CONCLUSIONS: This real-world pharmacovigilance analysis corroborates the known labeled safety profile of oritavancin and identifies multiple underemphasized signals not fully specified in the product label, involving the neurological, respiratory, cardiovascular, and musculoskeletal systems. These disproportionality signals from spontaneous reporting reflect only statistical associations rather than definitive causality, and warrant further verification to inform clinical safety monitoring.